Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

Vaccine candidate is expected to be submitted to UK regulatory authorities in Q2

- PMLiVE

How to design better medical outcomes: Combining patient insights and empathetic design

By adopting a design-led, solutions-based approach to communications, companies can help healthcare professionals (HCPs) to better meet the needs of their patients through their communications. While now may not feel...

Page & Page Health

- PMLiVE

Unlock the power of data to realise strategic goals

by Lisa Alderson

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

Roche Basel Switzerland

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

First SMA treatment approved in the EU that can be taken at home

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

- PMLiVE

Understand, identify and partner with HCPs to improve patient support

Patients are on the minds of HCPs, and at the forefront is engagement with disease awareness events

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

Langland appoints Mike Brightley as creative director in its advertising team

Brightley brings over 14 years of experience to the role

- PMLiVE

Fishawack Health acquires market access and HEOR consultancy PRMA Consulting

Acquisition adds presence in Asia-Pacific and Europe

- PMLiVE

EMA recommends new manufacturing sites for COVID-19 vaccines

EMA also recommends new storage temperature for Pfizer/BioNTech vaccine

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links